Uterine malignant mixed Müllerian tumor after adjuvant tamoxifen treatment for breast cancer

Background: Uterine malignant mixed Müllerian tumor (MMMT), also known as carcinosarcoma, is a biphasic tumor of the female genital tract and demonstrates both malignant epithelial (carcinoma) and mesenchymal (sarcoma) components. The authors present two cases of uterine MMMT after adjuvant tamoxifen (TAM) treatment for breast cancer and a review of the current literature. Cases: The patients presented with a complaint of abnormal uterine bleeding. They both had a history of breast cancer Stage IIB previously treated with modified radical mastectomy, at 51 and 78 months, respectively. They also had history of tamoxifen treatment 20 mg daily for seven and 73 months respectively. They underwent total abdominal hysterectomy with bilateral salpingooophorectomy and total omentectomy. Histopathology revealed a uterine MMMT. Postoperatively, they received adjuvant chemotherapy and radiotherapy. One of the patients died 26 months after initial surgery due to uterine MMMT. Conclusion: Uterine MMMT is a rare, highly-aggressive, and rapidly-progressing tumor associated with a poor prognosis. Postmenopausal patients, with prolonged adjuvant TAM treatment for breast cancer, are at increased risk for the development of uterine MMMT.

Uterine malignant mixed Müllerian tumor; Uterine carcinosarcoma; Tamoxifen; Treatment; Prognosis.

[1] Silverberg S.G., Kurman R.J. (eds.): “Tumors of the uterine corpus and gestational trophoblastic disease”. In: “Atlas of tumor pathology”, Washington, Armed Forces Institute of Pathology, 1991, 166.

[2] McCluggage W.G.: “Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?”. J. Clin. Pathol., 2002 55, 321.

[3] Young J.L., Jr., Percy C.L., Asire A.J., Berg J.W., Cusano M.M., Gloeckler L.A. et al.: “Cancer incidence and mortality in the United States, 1973-77”. Natl. Cancer Inst. Monogr., 1981, 57, 1.

[4] Harlow B.L., Weiss N.S., Lofton S.: “The epidemiology of sarcomas of the uterus”. J. Natl. Cancer Inst., 1986, 76, 399.

[5] Brooks S.E., Zhan M., Cote T., Baquet C.R.: “Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999”. Gynecol. Oncol., 2004, 93, 204.

[6] Sutton G., Kauderer J., Carson L.F., Lentz S.S., Whitney C.W., Gallion H.: “Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study”. Gynecol. Oncol., 2005, 96, 630.

[7] Zelmanowicz A., Hildesheim A., Sherman M.E., Sturgeon S.R., Kurman R.J., Barrett R.J. et al.: “Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors”. Gynecol. Oncol., 1998, 69, 253.

[8] Pecorelli S.: “Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium”. Int. J. Gynaecol. Obstet., 2009, 105, 103.

[9] Prat J.: “FIGO staging for uterine sarcomas”. Int. J. Gynecol. Obstet., 2009, 104, 177.

[10] Kanthan R., Senger J.L.: “Uterine carcinosarcomas (malignant mixed Müllerian tumours): a review with special emphasis on the controversies in management”. Obstet. Gynecol. Int., 2011, 2011, 470795.

[11] Silverberg S.G., Major F.J., Blessing J.A., Fetter B., Askin F.B., Liao S.Y. et al.: “Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases”. Int. J. Gynecol. Pathol., 1990, 9, 1.

[12] El-Nashar S.A., Mariani A.: “Uterine carcinosarcoma”. Clin. Obstet. Gynecol., 2011, 54, 292.

[13] Gorai I., Yanagibashi T., Taki A., Udagawa K., Miyagi E., Nakazawa T. et al.: “Uterine carcinosarcoma is derived from a single stem cell: an in vitro study”. Int. J. Cancer, 1997, 72, 821.

[14] de Brito P.A., Silverberg S.G., Orenstein J.M.: “Carcinosarcoma (malignant mixed mullerian (mesodermal) tumor) of the female genital tract: immunohistochemical and ultrastructural analysis of 28 cases”. Hum. Pathol., 1993, 24, 132.

[15] Thompson L., Chang B., Barsky S.H.: “Monoclonal origins of malignant mixed tumors (carcinosarcomas). Evidence for a divergent histogenesis”. Am. J. Surg. Pathol., 1996, 20, 277.

[16] Wada H., Enomoto T., Fujita M., Yoshino K., Nakashima R., Kurachi H. et al.: “Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors”. Cancer Res., 1997, 57, 5379.

[17] Ravazoula P., Androutsopoulos G., Zyli P., Michail G., Kardamakis D.M., Kourounis G.: “A clinicopathologic study on patients with endometrial cancer after adjuvant tamoxifen treatment for breast cancer: a single center experience”. Breast. J., 2006, 12, 578.

[18] Androutsopoulos G., Adonakis G., Gkermpesi M., Gkogkos P., Ravazoula P., Kourounis G.: “Expression of the epidermal growth factor system in endometrial cancer after adjuvant tamoxifen treatment for breast cancer”. Eur. J. Gynaecol. Oncol., 2006, 27, 490.

[19] Cohen I.: “Endometrial pathologies associated with postmenopausal tamoxifen treatment”. Gynecol. Oncol., 2004, 94, 256.

[20] McCluggage W.G., Abdulkader M., Price J.H., Kelehan P., Hamilton S., Beattie J. et al.: “Uterine carcinosarcomas in patients receiving tamoxifen. A report of 19 cases”. Int. J. Gynecol. Cancer, 2000, 10, 280.

[21] Bergman L., Beelen M., Gallee M., Hollema H., Benraadt J., van Leeuwen F.: “Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen”. Lancet, 2000, 356, 881.

[22] Curtis R.E., Freedman D.M., Sherman M.E., Fraumeni J.F. Jr.: “Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer”. J. Natl. Cancer Inst., 2004, 96, 70.

[23] Treilleux T., Mignotte H., Clement-Chassagne C., Guastalla P., Bailly C.: “Tamoxifen and malignant epithelial-nonepithelial tumours of the endometrium: report of six cases and review of the literature”. Eur. J. Surg. Oncol., 1999, 25, 477.

[24] Villena-Heinsen C., Diesing D., Fischer D., Griesinger G., Maas N., Diedrich K. et al.: “Carcinosarcomas – a retrospective analysis of 21 patients”. Anticancer Res., 2006, 26, 4817.

[25] Bharwani N., Newland A., Tunariu N., Babar S., Sahdev A., Rockall A.G. et al.: “MRI appearances of uterine malignant mixed mullerian tumors”. A.J.R. Am. J. Roentgenol., 2010, 195, 1268.

[26] Kernochan L.E., Garcia R.L.: “Carcinosarcomas (malignant mixed Mullerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics”. J. Natl. Compr. Canc. Netw., 2009, 7, 550.

[27] Vaidya A., Horowitz N., Oliva E., Halpern E., Duska L.: “Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma”. Gynecol. Oncol., 2006, 103, 684.

[28] Sartori E., Bazzurini L., Gadducci A., Landoni F., Lissoni A., Maggino T. et al.: “Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study”. Gynecol. Oncol., 1997, 67, 70.

[29] Sreenan J., Hart W.: “Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis”. Am. J. Surg. Pathol., 1995, 19, 666.

[30] Major F.J., Blessing J.A., Silverberg S.G., Morrow C.P., Creasman W.T., Currie J.L. et al.: “Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study”. Cancer, 1993, 71, 1702.

[31] Vorgias G., Fotiou S.: “The role of lymphadenectomy in uterine carcinosarcomas (malignant mixed mullerian tumours): a critical literature review”. Arch. Gynecol. Obstet., 2010, 282, 659.

[32] Nemani D., Mitra N., Guo M., Lin L.: “Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis”. Gynecol. Oncol., 2008, 111, 82.

[33] Galaal K., Kew F.M., Tam K.F., Lopes A., Meirovitz M., Naik R. et al.: “Evaluation of prognostic factors and treatment outcomes in uterine carcinosarcoma”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2009, 143, 88.

[34] Gonzalez Bosquet J., Terstriep S.A., Cliby W.A., Brown-Jones M., Kaur J.S., Podratz K.C. et al.: “The impact of multi-modal therapy on survival for uterine carcinosarcomas”. Gynecol. Oncol., 2010, 116, 419.

[35] Knocke T.H., Weitmann H.D., Kucera H., Kolbl H., Pokrajac B., Potter R.: “Results of primary and adjuvant radiotherapy in the treatment of mixed Mullerian tumors of the corpus uteri”. Gynecol. Oncol., 1999, 73, 389.

[36] Clayton Smith D., Kenneth Macdonald O., Gaffney D.K.: “The impact of adjuvant radiation therapy on survival in women with uterine carcinosarcoma”. Radiother. Oncol., 2008, 88, 227.

[37] Hoskins P.J., Le N., Ellard S., Lee U., Martin L.A., Swenerton K.D. et al.: “Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience”. Gynecol. Oncol., 2008, 108, 58.

[38] Galaal K., Godfrey K., Naik R., Kucukmetin A., Bryant A.: “Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma”. Cochrane Database Syst. Rev., 2011, 1, CD006812.

[39] Livasy C.A., Reading F.C., Moore D.T., Boggess J.F., Lininger R.A.: “EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma”. Gynecol. Oncol., 2006, 100, 101.

[40] Sawada M., Tsuda H., Kimura M., Okamoto S., Kita T., Kasamatsu T. et al.: “Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma”. Cancer Sci., 2003, 94, 986.

[41] Adonakis G., Androutsopoulos G.: “The role of ErbB receptors in endometrial cancer”. In: “Cancer of the uterine endometrium - advances and controversies”. Saldivar J.S. ed., Rijeka. InTech, 2012, 23.

[42] Iwasa Y., Haga H., Konishi I., Kobashi Y., Higuchi K., Katsuyama E. et al.: “Prognostic factors in uterine carcinosarcoma: a clinicopathologic study of 25 patients”. Cancer, 1998, 82, 512.

[43] Nordal R.R., Kristensen G.B., Stenwig A.E., Nesland J.M., Pettersen E.O., Trope C.G.: “An evaluation of prognostic factors in uterine carcinosarcoma”. Gynecol. Oncol., 1997, 67, 316.